GV, Alphabet Inc's venture capital arm, led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
from Reuters: Technology News https://reut.rs/301pils
via IFTTT
Home
Reuters: Technology News
Technology
Alphabet's GV leads funding in gene editing company Verve Therapeutics
0 comments: